Moat
8.0/10
Abbott combines regulated medical-device and diagnostics businesses, branded nutrition, broad distribution, clinical credibility, and scale across multiple health-care segments.
ABTQueued from the May 25, 2026 S&P 500 market-cap snapshot ranks 51-75; market data refreshed on May 25, 2026 using public market-data pages available near the snapshot date.
Abbott Laboratories
Abbott Laboratories makes medical devices, diagnostics, nutrition products, and branded generic medicines.
Metadata
Where this company sits
- Ticker
- ABT
- Rank snapshot
- ≈ 75
- Sector
- Health Care
- Industry
- Pharma & MedTech
- Region
- United States
- Index
- S&P 500 · Top 75 by market cap
Metrics
Scoring view
Every metric is paired with a short rationale. The numbers are deliberate, not divine.
Decentralizability
3.0/10
Core regulated devices and nutrition products are hard to decentralize, but patient-controlled data layers, open-source diabetes tools, and open nutrition databases create credible pressure around interfaces and coordination.
Profitability
7.0/10
Recent public market data reports positive trailing net income of roughly $6.25 billion on about $45.13 billion of trailing revenue, indicating durable profitability despite earnings pressure.
Price / Earnings
24.2x
CompaniesMarketCap reported Abbott's trailing P/E ratio at about 24.2 as of May 2026.
Market cap
$152.3B
StockAnalysis reported Abbott Laboratories market capitalization at about $152.25 billion as of May 22, 2026.
Freed-up capital potential
$13.7B
Derived from market cap, moat resistance, decentralizability, and profitability. It is a directional estimate of value capture that could come under pressure if open alternatives compound.
Narrative
Why the company matters
A short editorial overview plus the current thesis on moat strength and decentralization pressure.
Business mix
Abbott operates across medical devices, diagnostics, nutrition, and established pharmaceuticals, giving it a diversified health-care revenue base rather than a single-drug patent cycle.
The FreeStyle Libre diabetes-care platform and adult nutrition brands such as Ensure illustrate Abbott's mix of regulated device ecosystems and branded consumable products.
Registry posture
Abbott is a large, regulated incumbent with meaningful clinical, manufacturing, distribution, brand, and reimbursement advantages.
The most credible decentralization pressure is not a near-term clone of Abbott's regulated products, but open data, interoperable care infrastructure, cooperative nutrition formulation, and user-controlled monitoring layers around the products.
Moat reading
Abbott's moat is strongest where regulated clinical evidence, quality systems, reimbursement relationships, clinician trust, manufacturing scale, and brand familiarity compound. Continuous glucose monitoring and medical nutrition are not simple software markets; safety, compliance, distribution, and patient trust all matter.
The moat is not absolute. Open-source diabetes data tools show that motivated patients can build user-controlled monitoring and automation layers around commercial sensors, while open nutrition data can make product comparison and formulation more transparent.
Decentralization reading
Abbott's physical products remain difficult to decentralize because sensors, diagnostics, nutrition manufacturing, labeling, and medical claims are heavily regulated and quality-sensitive. That limits near-term substitution by informal open projects.
The decentralizable layers are coordination and information: patient-controlled CGM data stores, open artificial-pancreas software, open food databases, cooperative purchasing, and transparent formulation networks that reduce dependence on a single branded interface or nutrition label.
Products
Where the moat actually touches users
These pages zoom into the products and services that matter most to each company, the alternatives already nibbling at them, and 4 structured disruption concepts across the current product set.
4 disruption concepts tracked0 documented exceptions
FreeStyle Libre
Continuous glucose monitoring
2 conceptsFreeStyle Libre is Abbott's continuous glucose monitoring platform, pairing wearable glucose sensors with reader and smartphone-app workflows.
Ensure
Adult nutrition shakes and supplements
2 conceptsEnsure is Abbott's adult nutrition brand, offering shakes and supplements aimed at protein, calorie, vitamin, and specialty nutrition use cases.
Technology waves
Strategic lenses
These are the repo's explicit bias terms: the technologies expected to keep making incumbents less inevitable over time.
Microfactories and automated mini-home production
Small, software-defined manufacturing cells could make localized production less eccentric and more default.
- • Products with heavy branding but generic bill-of-materials profiles look increasingly vulnerable.
- • Logistics moats still matter, but their margin for arrogance should narrow.
- • Open-source production recipes can pressure both price and product differentiation.
Paper trail
Visible evidence trail
These sources shaped the scoring and writing. The site is opinionated, but it should not behave like it is improvising facts in a dark room.
Abbott Products and Solutions List
Abbott Laboratories · product page
Official product list showing Abbott's major product areas and references to FreeStyle Libre and Ensure.
Reviewed 2026-05-25
Abbott 2025 Annual Report
Abbott Laboratories · annual report
Primary annual-report source for Abbott's business segments, performance context, and nutrition and medical-device discussion.
Reviewed 2026-05-25
Abbott Laboratories Market Cap
StockAnalysis · market data
Market-data source reporting Abbott's market capitalization near the May 2026 snapshot date.
Reviewed 2026-05-25
Abbott Laboratories P/E Ratio
CompaniesMarketCap · market data
Market-data source for Abbott's May 2026 trailing P/E ratio and public-company valuation context.
Reviewed 2026-05-25